Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Inclusion Criteria: * ECOG PS 0-1 * Pathological tissue-confirmed unresectable locally advanced pancreatic cancer * Pancreatic cancer patients who have not received systemic anti-tumor therapy * Primary pancreatic cancer or at least one measurable lesion specified by RECIST1.1 standards * A life expectancy of \> 3 months * Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.0 ×109 cells/L, platelets ≥ 75×109 cells/L, hemoglobin ≥ 9.0 g/dl * AST\<2.5 × ULN(Upper Limit of Normal), ALT\<2.5 × ULN,creatinine ≤1.5xULN, total bilirubin \< ≤1.5 X ULN. Exclusion Criteria: * Diagnosed with other malignant diseases other than pancreatic cancer within three years before enrollment * Patients who are currently participating in interventional clinical research treatment or have received other research drugs or used research devices within four weeks before enrollment * Patients who have previously received anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T-cell receptors * Patients who have received systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within two weeks before enrollment * Abnormal results of blood routine examinations and liver and kidney and coagulation tests * Abnormal function of major organs (14 days before enrollment) * Women who are pregnant * Inability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document.